261 related articles for article (PubMed ID: 14995074)
1. X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction.
Hatse S; Bridger G; de Clercq E; Schols D
Cell Mol Biol (Noisy-le-grand); 2003; 49 Online Pub():OL443-52. PubMed ID: 14995074
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
3. CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.
Klasse PJ; Rosenkilde MM; Signoret N; Pelchen-Matthews A; Schwartz TW; Marsh M
J Virol; 1999 Sep; 73(9):7453-66. PubMed ID: 10438835
[TBL] [Abstract][Full Text] [Related]
4. The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivity.
Huskens D; Princen K; Schreiber M; Schols D
Virology; 2007 Jul; 363(2):280-7. PubMed ID: 17331556
[TBL] [Abstract][Full Text] [Related]
5. N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins.
Wang J; Babcock GJ; Choe H; Farzan M; Sodroski J; Gabuzda D
Virology; 2004 Jun; 324(1):140-50. PubMed ID: 15183061
[TBL] [Abstract][Full Text] [Related]
6. Optimal inhibition of X4 HIV isolates by the CXC chemokine stromal cell-derived factor 1 alpha requires interaction with cell surface heparan sulfate proteoglycans.
Valenzuela-Fernández A; Palanche T; Amara A; Magerus A; Altmeyer R; Delaunay T; Virelizier JL; Baleux F; Galzi JL; Arenzana-Seisdedos F
J Biol Chem; 2001 Jul; 276(28):26550-8. PubMed ID: 11352904
[TBL] [Abstract][Full Text] [Related]
7. Characterization and visualization of [125I] stromal cell-derived factor-1alpha binding to CXCR4 receptors in rat brain and human neuroblastoma cells.
Banisadr G; Dicou E; Berbar T; Rostène W; Lombet A; Haour F
J Neuroimmunol; 2000 Oct; 110(1-2):151-60. PubMed ID: 11024545
[TBL] [Abstract][Full Text] [Related]
8. Cyclic zinc-dithiocarbamate-S,S'-dioxide blocks CXCR4-mediated HIV-1 infection.
Takamune N; Misumi S; Shoji S
Biochem Biophys Res Commun; 2000 Jun; 272(2):351-6. PubMed ID: 10833417
[TBL] [Abstract][Full Text] [Related]
9. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
Esté JA; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
J Virol; 1999 Jul; 73(7):5577-85. PubMed ID: 10364306
[TBL] [Abstract][Full Text] [Related]
10. Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.
Gotoh K; Yoshimori M; Kanbara K; Tamamura H; Kanamoto T; Mochizuki K; Fujii N; Nakashima H
J Infect Chemother; 2001 Mar; 7(1):28-36. PubMed ID: 11406754
[TBL] [Abstract][Full Text] [Related]
11. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma.
Geminder H; Sagi-Assif O; Goldberg L; Meshel T; Rechavi G; Witz IP; Ben-Baruch A
J Immunol; 2001 Oct; 167(8):4747-57. PubMed ID: 11591806
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.
Fricker SP; Anastassov V; Cox J; Darkes MC; Grujic O; Idzan SR; Labrecque J; Lau G; Mosi RM; Nelson KL; Qin L; Santucci Z; Wong RS
Biochem Pharmacol; 2006 Aug; 72(5):588-96. PubMed ID: 16815309
[TBL] [Abstract][Full Text] [Related]
13. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
14. Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4(+) T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation.
Vicenzi E; Bordignon PP; Biswas P; Brambilla A; Bovolenta C; Cota M; Sinigaglia F; Poli G
J Virol; 1999 Sep; 73(9):7515-23. PubMed ID: 10438841
[TBL] [Abstract][Full Text] [Related]
15. The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.
Princen K; Hatse S; Vermeire K; Bridger GJ; Skerlj RT; De Clercq E; Schols D
AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1135-9. PubMed ID: 14709250
[TBL] [Abstract][Full Text] [Related]
16. Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.
Choi WT; Tian S; Dong CZ; Kumar S; Liu D; Madani N; An J; Sodroski JG; Huang Z
J Virol; 2005 Dec; 79(24):15398-404. PubMed ID: 16306611
[TBL] [Abstract][Full Text] [Related]
17. The two human CXCR4 isoforms display different HIV receptor activities: consequences for the emergence of X4 strains.
Duquenne C; Psomas C; Gimenez S; Guigues A; Carles MJ; Barbuat C; Lavigne JP; Sotto A; Reynes J; Guglielmi P; Mettling C; François V; Corbeau P
J Immunol; 2014 Oct; 193(8):4188-94. PubMed ID: 25230750
[TBL] [Abstract][Full Text] [Related]
18. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.
Chevigné A; Fievez V; Szpakowska M; Fischer A; Counson M; Plesséria JM; Schmit JC; Deroo S
Biochim Biophys Acta; 2014 May; 1843(5):1031-41. PubMed ID: 24480462
[TBL] [Abstract][Full Text] [Related]
19. Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.
Pontow S; Ratner L
J Virol; 2001 Dec; 75(23):11503-14. PubMed ID: 11689632
[TBL] [Abstract][Full Text] [Related]
20. Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.
Moncunill G; Armand-Ugón M; Clotet-Codina I; Pauls E; Ballana E; Llano A; Romagnoli B; Vrijbloed JW; Gombert FO; Clotet B; De Marco S; Esté JA
Mol Pharmacol; 2008 Apr; 73(4):1264-73. PubMed ID: 18182480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
